May 14, 2026 7:30 am EDT OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor
Apr 30, 2026 6:00 am EDT OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma
Apr 27, 2026 4:01 pm EDT OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET
Apr 16, 2026 7:20 am EDT OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes
Apr 13, 2026 6:00 am EDT OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor
Apr 02, 2026 5:15 pm EDT OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors
Mar 31, 2026 7:40 am EDT OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update
Mar 27, 2026 6:00 am EDT OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma
Mar 25, 2026 6:00 am EDT OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma